D-0526-2020 Class II Ongoing
FDA drug recall D-0526-2020 was initiated by AuroMedics Pharma LLC on Nov 6, 2019 and is designated Class II. Reason for recall: CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. The recall status is ongoing. Affected quantity: 69,696 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Dec 4, 2019
- Initiation Date
- Nov 6, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 69,696 bottles
Product Description
DG Health Acid Reducer Ranitidine Tablets 150 mg, 8-count carton, Distributed by: Dolgencorp LLC 100 Mission Ridge Goodletville TN 37072 NDC 55910-092-79
Reason for Recall
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
Distribution Pattern
nationwide
Code Information
Lot # NBSB19001DA3; Exp FEB 2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0526-2020
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026